Drug Profile

Insulin aspart - Sihuan Pharmaceutical

Alternative Names: insulin aspart 30

Latest Information Update: 22 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sihuan Pharmaceutical Holdings Group
Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preregistration Diabetes mellitus

Most Recent Events

27 Jan 2022 Preregistration for Diabetes mellitus in China (Parenteral)
27 Jan 2022 The National Medical Products Administration (NMPA) accepts BLA for insulin aspart for Diabetes mellitus
19 Aug 2019 Phase-III clinical trials in Diabetes mellitus in China (Parenteral) before July 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com